GlassScriptPhysician profile
Anna Somerto
NPI 1336107150
$5,382.40
in general payments reported to CMS, 2019-2025
28 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $256 · 2021: $563 · 2022: $1,038 · 2023: $866 · 2024: $1,410 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,369.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,367.97 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Sk Life Science, INC. | $807.66 | 2022-2025 | Xcopri |
| Pfizer INC. | $592.70 | 2023-2025 | |
| Livanova USA, INC. | $448.13 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Lilly USA, LLC | $441.30 | 2020-2025 | Emgality, Reyvow |
| Biohaven Pharmaceuticals, INC. | $376.58 | 2020-2021 | |
| Cala Health, INC. | $215.85 | 2022-2023 | Cala Trio |
| Biohaven Pharmaceutical Holding Company LTD. | $208.01 | 2022 | |
| Sumitomo Pharma America, INC. | $141.41 | 2023-2024 | Aptiom |
| Teva Pharmaceuticals USA, INC. | $132.02 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $71.00 | 2024-2025 | |
| Stimwave Technologies Incorporated | $65.16 | 2020-2022 | |
| Eisai INC. | $63.13 | 2025 | |
| Novartis Pharmaceuticals Corporation | $58.05 | 2019-2021 | |
| Allergan, INC. | $54.76 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $53.48 | 2019-2020 | |
| Nalu Medical, INC. | $42.66 | 2021-2024 | Nalu Neurostimulation System |
| Acadia Pharmaceuticals INC | $42.12 | 2024-2025 | Daybue |
| Medtronic USA, INC. | $33.53 | 2020 | |
| Lundbeck LLC | $29.63 | 2025 | |
| Biogen, INC. | $25.00 | 2020 | |
| Relievant Medsystems, INC. | $23.40 | 2021 | |
| Alexion Pharmaceuticals, INC. | $21.14 | 2023 | Ultomiris |
| Boston Scientific Corporation | $18.36 | 2023 | Wavewriter Alpha Prime 16 |
| Globus Medical, INC. | $14.70 | 2025 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.30 | 2024 | Relistor |
| Genentech USA, INC. | $12.85 | 2019 | |
| Grt US Holding, INC. | $8.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Somerto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.